Patients whose incomes and assets place them just above the threshold for the low-income subsidies and those who received prescription drug coverage prior to the availability Medicare Part D are not likely to benefit from the new coverage plan.
A physician advocate who has taken public advocacy stances against the federal government while employed by the government talks about the conflicts that arise between medicine and politics.
The objective is to compare the costs of providing the same level of quality. When resource-use and quality measures are juxtaposed, the resources used to provide the same level of quality can be compared.
Eitan Neidich, Alon B. Neidich, David A. Axelrod, MD, and John P. Roberts, MD
Geographic disparities in availability of organs for transplant have spawned for-profit companies that help patients get on waitlists in more than one region and arrange travel for them if an organ becomes available.
The picture that emerges from study of physician economic behavior is mixed, but from the intensity of responses by some professional societies to Medicare's coding modifier proposal, it appears that economic incentives matter a lot to many of their members.
The NRMP’s new “all-in” policy requires every residency program to fill every first-year position either exclusively through the match or outside of it. Programs that continue to offer prematches will operate outside the match.
Roy Ahn, MPH, ScD, Kristina Tester, Zaid Altawil, MD, and Thomas F. Burke, MD
To promote good practices, non-governmental organizations (NGOs) working in global health should adopt and follow rules of professional conduct that put communities’ wants and needs over those of the NGOs.
AMA J Ethics. 2015;17(5):456-460. doi:
10.1001/journalofethics.2015.17.5.pfor2-1505.
Geoff Hollett, PhD and Jennie B. Jarrett, PharmD, PhD, MMedEd
The Strategic National Stockpile is a national system maintained by the US federal government to deliver medical supplies during emergencies, and it needs administrative changes.
AMA J Ethics. 2024;26(4):E315-320. doi:
10.1001/amajethics.2024.315.
Elderly persons should not be excluded from participation in clinical trials for cardiovascular drugs since that population comprises the largest number of patients with cardiovascular disease.